Edition:
United States

Sanofi SA (SNY)

SNY on New York Consolidated

49.33USD
23 Jun 2017
Change (% chg)

$-0.28 (-0.56%)
Prev Close
$49.61
Open
$49.49
Day's High
$49.49
Day's Low
$49.12
Volume
3,888,850
Avg. Vol
1,778,992
52-wk High
$50.24
52-wk Low
$36.81

SNY

Chart for SNY

About

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company's segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including... (more)

Overall

Beta: 0.88
Market Cap(Mil.): $123,958.60
Shares Outstanding(Mil.): 2,520.93
Dividend: 1.64
Yield (%): 3.33

Financials

  SNY Industry Sector
P/E (TTM): 24.35 14.09 19.01
EPS (TTM): 2.03 -- --
ROI: -- -6.73 -5.03
ROE: -- -6.18 -4.28

Germany's Merck gets EU backing for oral MS drug

(This June 23 story corrects second paragraph to show that the recommendation is to approve the relapsing forms, not the relapsing-remitting form of MS.)

3:23pm EDT

CORRECTED-Germany's Merck gets EU backing for oral MS drug

FRANKFURT, June 23 Germany's Merck KGaA has won a key recommendation to become a late entrant to the market for oral multiple sclerosis (MS) drugs in Europe, six years after its first attempt to launch the cladribine pill failed.

3:20pm EDT

BRIEF-Rosa & Co announces renewal of multi-yr research agreement with Sanofi

* Rosa & Co announces renewal of multi-year research agreement with Sanofi

Jun 20 2017

Sanofi chief says U.S. Supreme Court ruling on biologics has "immediate impact"

PARIS The U.S Supreme Court decision to speed access to copycat biologics drugs on Monday was expected but has an "immediate impact", Sanofi Chief Executive told Reuters.

Jun 16 2017

Sanofi chief says U.S. Supreme Court ruling on biologics has "immediate impact"

PARIS The U.S Supreme Court decision to speed access to copycat biologics drugs on Monday was expected but has an "immediate impact", Sanofi Chief Executive told Reuters.

Jun 16 2017

Sanofi chief says U.S. Supreme Court ruling on biologics has "immediate impact"

PARIS, June 16 The U.S Supreme Court decision to speed access to copycat biologics drugs on Monday was expected but has an "immediate impact", Sanofi Chief Executive told Reuters.

Jun 16 2017

BRIEF-Parexel collaborates with Sanofi to advance use of wearable devices in life science industry

* Parexel collaborates with Sanofi to advance the use of wearable devices in life science industry

Jun 15 2017

Sanofi to invest further in biologics

PARIS Sanofi announced plans to invest 600 million euros ($673 million) annually over the next two to three years in the field of biologics production, an area of strong growth potential.

Jun 14 2017

UPDATE 1-Sanofi to invest further in biologics

* plans annual spending of 600 mln eur in biotechnology production

Jun 14 2017

Sanofi to invest further in biologics

PARIS, June 14 French drugmaker and healthcare group Sanofi on Wednesday announced plans to invest 600 million euros ($673 million) annually over the next two to three years in the field of biologics, seen as an area with a strong growth potential.

Jun 14 2017

More From Around the Web

Competitors

Earnings vs. Estimates